Please login to the form below

Not currently logged in
Email:
Password:

GLP-1 agonists

This page shows the latest GLP-1 agonists news and features for those working in and with pharma, biotech and healthcare.

Novo Nordisk set to acquire Emisphere Technology for $1.8bn

Novo Nordisk set to acquire Emisphere Technology for $1.8bn

Novo won US Food and Drug Administration (FDA) approval for Rybelsus in September 2019, when it became the first oral alternative to injectable GLP-1 agonists. ... Rothwell, chairman of Emisphere. Novo’s GLP-1 agonist franchise also includes Ozempic

Latest news

  • Lilly’s Trulicity scores CV reduction indication in the US Lilly’s Trulicity scores CV reduction indication in the US

    The once-weekly GLP-1 agonist has been available in the US since 2014, when it first gained FDA approval to improve glycaemic control in adults with type 2 diabetes. ... The new MACE approval could help Lilly in its fight for market share with other

  • Novo bolstered by new diabetes, obesity products Novo bolstered by new diabetes, obesity products

    The once-weekly injectable GLP-1 agonist has continued to offset declines of Novo’s older drugs, including the one-daily shot Victoza (liraglutide). ... It is the first oral alternative to injectable GLP-1 agonists, and has also been touted by Novo as

  • Novo Nordisk gets FDA okay for new diabetes hope Novo Nordisk gets FDA okay for new diabetes hope

    Potential to combat increasing competition and pricing pressures. Novo Nordisk has FDA approval for the first oral alternative to injectable GLP-1 agonists, which the company thinks could be a blockbuster ... product. The US regulator has approved the

  • Novo Nordisk shareholder revolt reaches Europe Novo Nordisk shareholder revolt reaches Europe

    Novo Nordisk has latterly become less reliant on sales of its insulin products as newer products, particularly GLP-1 agonists Victoza (liraglutide) and Ozempic (semaglutide), have increased their share of revenues.

  • Lilly’s Trulicity cuts heart and kidney risks in diabetes by 12% Lilly’s Trulicity cuts heart and kidney risks in diabetes by 12%

    Lilly revealed last November that the top-line data with the once-weekly GLP-1 agonist was positive, and over the weekend at the American Diabetes Association meeting, presented the detailed ... Trulicity's growth to date has stemmed largely from its once

More from news
Approximately 8 fully matching, plus 40 partially matching documents found.

Latest Intelligence

  • Sourcing R&D innovation: why pharma companies need to evolve their business models Sourcing R&D innovation: why pharma companies need to evolve their business models

    Examples of this approach include developing statins for the treatment of dyslipidemia, angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) for hypertension, and glucagon-like peptide 1 ... 1) receptor agonists for

  • Cortellis Drugs to Watch in 2020 report Cortellis Drugs to Watch in 2020 report

    Upon interaction with the GLP-1 receptor, it stimulates the secretion of insulin in a glucose-dependent manner. ... It faces competition from entrenched generic metformin and sulphonylureas, as well as from more novel drug classes, particularly SGLT-2,

  • Deal Watch table for January 2015 Deal Watch table for January 2015

    Licence collaboration agreement. 1, 110. Janssen/ Depomed. Nucynta [tapentadol] franchise including extended release tablets and oral solutions. ... Asset acquisition. 142.  Amunix/Naia. To develop glucagon peptide agonists GLP-1-XTEN and GLP-2-XTEN in

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Anthill Agency

Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...

Latest intelligence

Want to give perfect client service? Tough luck, you’re human
In this article an ex-client of mine, Liz Skrbkova, and I explore the (unhelpful) pressures of trying to perfect the client-agency relationship...
WHITE PAPER: Why do men die younger?
It’s a commonly accepted fact that women outlive men. Wherever you live, there’s a good chance that men will die on average eight years earlier than women. Is this an...
3 tips to show patient diversity in your clinical trial materials
Here are some useful tips to help get your hands on authentically diverse stock photos....

Infographics